Jacques Buvat

TL;DR: A standardized process for diagnosis and treatment of Testosterone (T) deficiency is proposed, and the knowledge on T therapy (Tth) and prostate and cardiovascular safety is updated.

TL;DR: A body of molecular and clinical evidence supports the use of TRT in hypogonadal patients with ED, although the benefit-risk ratio is uncertain in advanced age, and an improved diagnosis and individualized management is desirable.

TL;DR: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination and it is advocated that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.

TL;DR: There is no compelling evidence that testosterone treatment causes prostate cancer or its progression in men without severe testosterone deficiency (TD), and men with erectile dysfunction, hypoactive sexual desire and retarded ejaculation, as well as those with visceral obesity and metabolic diseases, should be screened for TD and treated.

TL;DR: Dapoxetine significantly improved all aspects of PE and was generally well tolerated in this broad population of men.